Huahai pharmaceutical reports H1 2025 performance, secures FDA approval

Zhejiang Huahai Pharmaceutical Co., Ltd. reported a challenging first half of 2025, with operating revenue of CNY 4,516,353,788.97 and net profit attributable to shareholders of CNY 409,487,616.19. This represents a 45.30% decrease in net profit compared to the previous year, primarily due to intensified competition, price declines, increased R&D investment, and foreign exchange rate fluctuations. The company’s total assets grew by 4.96% to CNY 21,265,898,469.48.

In a key development, the company's subsidiary, Prinston Pharmaceutical, Inc., received FDA approval for Dicyclomine Hydrochloride Tablets (20 mg). This enhances its product portfolio and market competitiveness in the US, where the drug’s sales reached approximately $17.6 million in 2024. Furthermore, the company authorized its management to apply for credit lines totaling up to CNY 1.623 billion for its subsidiaries, with a maximum term of five years.

Controlling shareholder Chen Baohua and major shareholder Zhou Minghua made pledges related to their holdings. Zhou Minghua pledged 15,000,000 shares, bringing his total pledged shares to 93,980,000, representing 41.88% of his holdings and 6.28% of the company's total share capital. These pledges collateralize financing for Shanghai International Medical Center Co., Ltd.